Kanuma
What Kanuma is used for
Kanuma is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Kanuma
- Active substance
- sebelipase alfa
- Disease area
- Lipid Metabolism, Inborn Errors
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16
- Marketing authorisation holder
- Alexion Europe SAS
- Authorised in the EU since
- 2015
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kanuma used for?
Kanuma is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.
What is the active substance in Kanuma?
Kanuma contains sebelipase alfa.
Who makes Kanuma?
The EU marketing authorisation holder is Alexion Europe SAS.
Is Kanuma an orphan medicine?
Yes. Kanuma is designated an orphan medicine in the EU, for a rare disease (Lipid Metabolism, Inborn Errors).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU